Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Thera CS (NQ: NTLA )

26.34 +0.49 (+1.90%)
Streaming Delayed Price Updated: 10:27 AM EDT, Jun 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
EVP And Chief Medical Officer Of Intellia Therapeutics Trades $340K In Company Stock
David Lebwohl, EVP And Chief Medical Officer at Intellia Therapeutics (NASDAQ:NTLA), made a large buy and sell of company shares on October 14, according to a new SEC filing. What... 
Via Benzinga
Topics Regulatory Compliance
Exposures Legal Regulatory
2 Gene-Editing Stocks to Have on Your Radar Right Now
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies. 
Via The Motley Fool
Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week
A key gene-editing readout had Cathie Wood shuffling her portfolio. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
Intellia Therapeutics & UiPath Elliott Wave Analysis
US Stocks NTLA &PATH technical analysis, Elliott Wave forecast & trading. 
Via Talk Markets
Stock Trading: Intellia Therapeutics Inc & Zillow Technical Analysis
Intellia and Zillow technical analysis, Elliott Wave forecast. 
Via Talk Markets
Where Intellia Therapeutics Stands With Analysts
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed t... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
Intellia To Test Second CRISPR Therapeutic In Hereditary Angioedema Patients
The New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) Phase 1/2 study of NTLA-2002... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2021
Upgrades Wolfe Research upgraded the previous rating for PACCAR Inc (NASDAQ: 
Via Benzinga
Technical Analysis : Pinduoduo (PINS) & Intellia Therapeutics (NTLA)
Here's a technical analysis of two stocks: Pinduoduo (PDD) & Intellia Therapeutics. 
Via Talk Markets
The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 7) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Exposures Product Safety
CareDx & Intellia Therapeutics Elliott Wave Analysis
At this point the flat correction into wave (4) could be completed, if not we are just missing one last leg down. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For September 24, 2021
Upgrades Berenberg upgraded the previous rating for Tenable Holdings Inc (NASDAQ: 
Via Benzinga
Intellia To Test CRISPR-Engineered TCR-T Cell Candidate In Acute Myeloid Leukemia Patients
The FDA has signed off Intellia Therapeutics Inc's (NASDAQ: NTLA) investigational new drug (IND) application for NTLA-5001. Related Content: Intellia... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The company's market cap stands at $152.7 million. Phio... 
Via Benzinga
Where Intellia Therapeutics Stands With Analysts
Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst rati... 
Via Benzinga
Why Intellia Therapeutics' Stock Is Trading Higher Today
Intellia Therapeutics Inc (NASDAQ:NTLA) is trading si... 
Via Benzinga
Why Intellia Therapeutics Shares Are Trading Higher Today
... 
Via Benzinga
Forget About the Genomic Revolution, the Proteomic Revolution Is Coming
Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. 
Via InvestorPlace
Gene Editing Stocks: The Trial News Lifting NTLA, CRSP and EDIT Stocks Today
Today, gene editing stocks are getting a big boost after an intriguing data release by Editas for the company's new SLEEK technology. 
Via InvestorPlace
US Stocks: AME, AVAV, NIO, NTLA, PDD & SNAP Technical Analysis
Technical stocks analysis: Ametek, AeroVironment, Nio Inc, Intellia Therapeutics, Pinduoduo, and Snap. 
Via Talk Markets
Intellia Therapeutics, inc (NTLA) Q2 2021 Earnings Call Transcript
NTLA earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
10 Biggest Price Target Changes For Friday
Piper Sandler boosted the price target for Moderna, Inc. (NASDAQ: MRNA) from $246 to $445. Moderna shares fell 1.6% to $409.55 in pre-market trading. Needham cut the price... 
Via Benzinga
99 Biggest Movers From Yesterday
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a... 
Via Benzinga
Why Shares of Intellia Therapeutics Are Jumping Today
More progress in the pipeline has investors bullish on the company's shares. 
Via The Motley Fool
Gene Editing Stocks: Why EDIT, NTLA, CRSP Stocks Are Climbing Today
Today, investors in gene editing stocks are seeing a lot of green as earnings were announced along with business updates from key players. 
Via InvestorPlace
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies. Most pharma majors reported strong quarterly results.... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.